The chemist examined the role of activated oxygen molecules in biological processes.
Outsourcing is still the rule and data analysis, the bottleneck.
November 1, 2014|
In May, The Scientist, in collaboration with Frost & Sullivan, an international market intelligence and consulting firm, conducted a brief survey of our readers about their use of next-generation sequencing (NGS) technology. The majority of NGS work is focused on disease-related and basic research. While only 40% of respondents perform in-house NGS, that percentage is expected to increase by 4% in the next year. Half of those surveyed plan to perform RNA-Seq in the next two years. The most significant bottleneck in NGS workflow is the length of time spent analyzing and interpreting data, with 32% of the respondents outsourcing the work to in-house bioinformatics colleagues or third-party companies.
—Christi Bird, Senior Industry Analyst, Life Sciences, Frost & Sullivan
All figures are rounded
November 20, 2014
Words do not substitute for knowledge. What's the difference between "massively, massively parallel sequencing" and "deep sequencing" and just DNA sequencing" Michael Lerman, Ph.D., M.D.